Prolonged intake of chlorambucil for ovarian cancer.
作者信息
Khalil A M, Khatib R A, Shamseddine A I, Sharara N H, Seoud M A
机构信息
Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Lebanon.
出版信息
Eur J Obstet Gynecol Reprod Biol. 1995 May;60(1):85-6. doi: 10.1016/0028-2243(94)02018-3.
PMID:7635238
Abstract
The use of alkylating agents has been reported to be a cause of secondary leukemia particularly in patients surviving for 2 years or more after treatment of ovarian carcinoma. The risk of developing leukemia is possibly related to the duration of treatment and the total dose of alkylating agents administered. We report a patient with epithelial ovarian carcinoma who received chlorambucil for 130 consecutive months with no clinical or laboratory evidence of leukemia.
摘要
Zotero 插件